Loomis, Sayles & Company
INSM icon

Loomis, Sayles & Company’s Insmed INSM Stock Holding History

Loomis, Sayles & Company’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9M Sell
194,982
-4,973
-2% -$765K 0.04% 159
2025
Q4 		$34.8M Sell
199,955
-292,341
-59% -$53.3M 0.04% 154
2025
Q3 		$70.9M Sell
492,296
-301,273
-38% -$36.9M 0.08% 78
2025
Q2 		$79.9M Sell
793,569
-215,897
-21% -$16.5M 0.1% 72
2025
Q1 		$77M Sell
1,009,466
-165,325
-14% -$12.6M 0.11% 74
2024
Q4 		$81.1M Sell
1,174,791
-35,396
-3% -$2.55M 0.1% 80
2024
Q3 		$88.3M Sell
1,210,187
-16,539
-1% -$1.22M 0.12% 75
2024
Q2 		$82.2M Sell
1,226,726
-265,068
-18% -$10.3M 0.11% 72
2024
Q1 		$40.5M Sell
1,491,794
-839,711
-36% -$23.5M 0.06% 158
2023
Q4 		$72.3M Sell
2,331,505
-51,534
-2% -$1.34M 0.11% 86
2023
Q3 		$60.2M Buy
2,383,039
+769,443
+48% +$17.6M 0.1% 94
2023
Q2 		$34M Sell
1,613,596
-14,922
-0.9% -$283K 0.05% 170
2023
Q1 		$27.8M Buy
1,628,518
+401,418
+33% +$7.8M 0.05% 188
2022
Q4 		$24.5M Sell
1,227,100
-29,357
-2% -$567K 0.05% 200
2022
Q3 		$27.1M Sell
1,256,457
-15,165
-1% -$364K 0.05% 178
2022
Q2 		$25.1M Sell
1,271,622
-6,471
-0.5% -$136K 0.05% 201
2022
Q1 		$30M Sell
1,278,093
-24,417
-2% -$567K 0.04% 230
2021
Q4 		$35.5M Buy
1,302,510
+67,849
+5% +$1.94M 0.04% 230
2021
Q3 		$34M Buy
1,234,661
+459,411
+59% +$12.1M 0.04% 228
2021
Q2 		$22.1M Sell
775,250
-15,682
-2% -$465K 0.03% 291
2021
Q1 		$26.9M Sell
790,932
-3,215
-0.4% -$123K 0.03% 252
2020
Q4 		$26.4M Buy
+794,147
New +$29M 0.03% 228

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Loomis, Sayles & Company's INSM Position: Q1 2026 in Review

Loomis, Sayles & Company reduced its Insmed (INSM) stake by 2.5% in Q1 2026, selling an estimated $765K and leaving 194,982 shares worth $31.9M. The position accounts for 0.04% of the portfolio, ranked #159.

Loomis, Sayles & Company first reported a position in INSM in Q4 2020 and has held it in 22 quarters since. The position peaked at $88.3M in Q3 2024. 670 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Loomis, Sayles & Company held 194,982 shares of Insmed worth $31.9M as of Q1 2026.
  • Loomis, Sayles & Company sold 4,973 Insmed shares in Q1 2026, an estimated $765K.
  • Insmed made up 0.04% of Loomis, Sayles & Company's portfolio in Q1 2026, its #159 holding.
  • Loomis, Sayles & Company first reported a position in Insmed in Q4 2020 and has held it in 22 quarters since.
  • Loomis, Sayles & Company's Insmed position peaked at $88.3M in Q3 2024.
  • 670 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.